Skip to Content

Anthony Fauci. Photo Oliver Contreras/EPA via The Conversation.

Coronavirus: scientists promoting chloroquine and Remdesivir are acting like sports rivals

In the struggle to find a cure for coronavirus, scientists are denigrating each other like sportsmen or boxers before a match. Which cure will win: Hydroxychloroquine or Remdesivir?

Published: May 29, 2020, 11:48 am

    Read more

    Rivals Usain Bolt and Justin Gatlin trash-talked each other before the 2016 Olympics, with Bolt calling Gatlin “old man”, and Gatlin calling Bolt “middle aged”. The banter was entertaining but vanished into insignificance when Bolt won. After the race, both athletes shook hands and accepted the result.

    Something like trash-talking is happening in the race for a treatment for COVID-19, but – unlike with Bolt and Gatlin’s race, which decided the matter – there is no fair test of the two top contending treatments being conducted. The two competing treatments getting the most press are chloroquine, or its cousin hydroxychloroquine (usually given with an antibiotic), and remdesivir. Like almost all medical treatments, they both have benefits and harms.

    Hydroxychloroquine is promoted by world-renowned French virologist Didier Raoult, who looks like a rock star. Remdesivir is being endorsed by Donald Trump’s scientific adviser, Anthony Fauci.

    Fauci claimed that Raoult’s treatment may have “no effect”, and Raoult returned the favour by accusing Fauci’s trial of “surprisingly” changing outcomes mid-stream (death rate was initially the primary outcome measure but this was replaced with the time it took patients to recover). Missing from this exchange is a call for a fair head-to-head test of the two treatments.

    ‘Rock star’ Raoult.

    Hydroxychloroquine

    Hydroxychloroquine is a cheap treatment for malaria, which some test-tube studies suggest inhibits the growth of viruses such as the novel coronavirus. Raoult noticed that it appeared to be very effective in most of his COVID-19 patients. He conducted a few trials that seemed to show a large effect, but the trials were small (fewer than 80 patients) and it seemed to have serious side-effects in some patients.

    Raoult claims that patients in his hospital wouldn’t have agreed to a “fair test” of his treatment against any other (or a placebo) because they wanted hydroxychloroquine. This may be true in his hometown of Marseilles, where he has celebrity status, but not elsewhere. Also, the fact that he has fans in Marseilles should not have stopped him from publishing a protocol for a comparative trial.

    Without a fair test, fans of remdesivir (and critics of hydroxychloroquine) will continue to find flaws with Raoult’s study.

    Remdesivir

    Remdesivir, a drug developed by Gilead Sciences, has been shown to work in monkeys, but it flopped in the first trial for treating humans with COVID-19.

    Revealing the dangerously non-transparent nature of the science in this area, the World Health Organization (WHO) initially posted the results of the failed trial and subsequently took the data down. Simultaneously, Gilead Sciences accused the WHO of “misrepresenting” the trial.

    Another trial that didn’t test the drug against a control group, reported by industry-funded authors, found that 36 of the 53 patients who took remdesivir had improved lung function. Yet 60% of the patients had at least one side-effect, including abnormal liver function.

    Most recently, the US National Institutes of Health funded a trial comparing remdesivir with placebos in 1,000 patients. The drug seemed to reduce the length of stay in hospital from 14 days – which was how long those who took a placebo were in hospital – to 11 days. However, Fauci announced the results on national television before the study was reviewed, so nobody can confirm independently whether it was a fair test.

    A problem with Fauci’s trial is that the protocol was changed after the trial started. Initially, they were supposed to measure death, which is barely susceptible to bias. They changed this to length of stay in hospital, which is more susceptible to bias. Changing the protocol mid-stream is sometimes justified, but no rationale was provided.

    Even if the trial of remdesivir versus placebo had no flaws, believers in hydroxychloroquine could say that their treatment would have fared better if it had been compared directly.

    There is plenty more to the story of hydroxychloroquine and remdesivir. Last time I checked, there were almost 100 trials of either hydroxychloroquine or remdesivir registered worldwide. The problem is that none of them amounts to a fair side-by-side trial. A fair comparative test of a treatment is (conceptually) no more complex than a 100m race. Such comparative tests are the heart of evidence-based medicine.

    In brief, we need a randomised, double-blind trial that compares one treatment against another. Such a trial uses (something like) flipping a coin to decide who gets what. Otherwise, if people choose which treatment they are on, it could turn out that, say, younger, healthier people chose one treatment over another. That would be like giving one of the treatments a head start. Blinding involves hiding knowledge of who got what (by making both treatments in the trial look the same). Blinding prevents people’s beliefs and expectations (which can influence outcomes) from influencing the outcome. Fauci and Raoult know this, and they have chosen not to ask for a fair test.

    There is a silver lining to this evidence cloud in the form of an Oxford-based trial called RECOVERY. RECOVERY compares several options for treating COVID-19, including hydroxychloroquine. However, it does not include remdesivir.

    In a recent interview with the Financial Times, the lead researcher of RECOVERY claimed that there was not enough remdesivir available. Also, the results of Fauci’s (unpublished) trial were not available at the time they designed the Oxford trial, so the RECOVERY researchers only had access to the earlier small trial in which remdesivir failed.

    Sick patients are concerned with objective facts that can answer the question: “What is the best treatment for my COVID-19?” Until a head-to-head study of the two drugs is conducted, this vital question will not be answered satisfactorily. Instead, we will continue to get biased opinions, sometimes fuelled by conspiracy theories that inform treatment decisions.

    For the sake of patients, energy spent promoting these partisan opinions need to be redirected towards conducting fair tests. Until this happens, these readily available objective facts will be obscured beneath biased opinions. As a result, more patients than necessary will remain ill and die.The Conversation

    Jeremy Howick, Director of the Oxford Empathy Programme, University of Oxford

    This article is republished from The Conversation under a Creative Commons license. Read the original article.

    opinion@freewestmedia.com

    Exclusively for freewestmedia.com

    Consider donating to support our work

    Help us to produce more articles like this. FreeWestMedia is depending on donations from our readers to keep going. With your help, we expose the mainstream fake news agenda.

    Keep ​your language polite​. Readers from many different countries visit and contribute to Free West Media and we must therefore obey the rules in​,​ for example​, ​Germany. Illegal content will be deleted.

    If you have been approved to post comments without preview from FWM, you are responsible for violation​s​ of​ any​ law. This means that FWM may be forced to cooperate with authorities in a possible crime investigation.

    If your comments are subject to preview ​by FWM, please be patient. We continually review comments but depending on the time of day it can take up to several hours before your comment is reviewed.

    We reserve the right to del​ete​ comments that are offensive, contain slander or foul language, or are irrelevant to the discussion.

    • pcl

      Most of the Hydroxychloroquine trials cited by the mainstream media did NOT include zinc, which was present in all the most successful trials and treatments. Reporting only on trials without zinc is a naked attempt to falsely discredit Hydroxychloroquine.

    Opinion

    Sweden’s decaying democracy

    A journalist is arrested and dragged out of the Gothenburg Book Fair because he politely asked a powerful politician... the wrong questions about his support for the ethnically-cleansed Zimbabwean dictatorship. Not only journalists, but academics and bloggers are being hounded by the leftist establishment daily. And the leftists have all the nasty instruments of the state at their disposal. Citizen reporter Fabian Fjälling looks into their excesses.

    The geopolitical future of Nordic countries

    Between unity and disunity, independence and foreign interference: Nordic countries have to either choose between creating an independent neutral block in the North, or seeing the region being divided between the great powers.

    Russian, Chinese intelligence: ISIS heading for Central Asia with US cover

    Operatives of the crumbling Islamic State in Syria and Iraq (ISIS) are moving to new battlegrounds near the Russian border, intelligence sources have revealed.

    The unraveling of US/Russian relations

    Washington has taken nuclear war against Russia from a hypothetical scenario to a real danger that threatens the future of humanity. 

    Hero commander killed in Syria – when the war is nearly won

    For most Syrians it came as a shock: One of the most popular military commanders of the Syrian Arab Army, Issam Zahreddine, was killed on 18 October 2017.

    What Is The Obama Regime Up To?

    Obama has announced new sanctions on Russia based on unsubstantiated charges by the CIA.

    Kevork Almassian: Aleppo resisted and triumphed

    OPINIONEven the Western Mainstream Media couldn’t hide the celebrations and the joy of the civilians in Aleppo, who expressed their gratitude to the Syrian Army and Russia.

    Lebanon’s new president: Michel Aoun

    COMMENT

    Ukrainian Terror and Donbass referendum: What we can learn from the latest events in Donetsk

    OPINIONThe assassination of Donbass field commander Arsen “Motorola” Pavlov on October 16 can be seen as a new escalation of the war scenario in former Eastern Ukraine. The successful elimination of one of the most popular commanders of the independence war of Donbass brought that geopolitical hotspot – despite the events in Syria´s Aleppo – back in Western mainstream media.

    Renaud Camus

    The Great Replacement and the tragedy of Sweden

    Go to archive